Q-omics provides the consensus-scored TPT1P14 profile across patient tissues and cancer cell-line models. TPT1P14 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TPT1P14 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TPT1P14 RNA expression shows 4,650 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight BRCA, KIRC, and UCEC as cancer lineages where TPT1P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPT1P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPT1P14 survival associations across molecular data types. TPT1P14 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPT1P14 RNA expression–survival associations across cancer types. High TPT1P14 expression shows unfavorable associations in BRCA, STAD, READ, LUAD and KICH, but favorable associations in LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .033). Together, the overview and detailed table identify BRCA as the clearest survival context for TPT1P14 RNA expression.
This table summarizes TPT1P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TPT1P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPT1P14 shows lower tumor expression in LIHC and COAD and higher tumor expression in KIRC, HNSC, LUAD and STAD. The KIRC box plot shows higher TPT1P14 RNA expression in tumor versus normal tissue (log2 FC = +0.064, t-test p = .001).
This table shows molecular features associated with TPT1P14 in patient tissues and cancer cell lines. In patient samples, TPT1P14 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
